IP Library Granted Patent US 11,981,940
Granted Patent B2
US 11,981,940 · App. 17/929,162 · Granted May 14, 2024

DNA modifying enzymes and active fragments and variants thereof and methods of use

Inventors: Tyson D. Bowen (Morrisville, NC); Alexandra Briner Crawley (Cary, NC); Tedd D. Elich (Durham, NC)
Assignee: LifeEDIT Therapeutics, Inc.
C12N9/22C12N15/63C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,981,940
App. No.
17/929,162
Granted
May 14, 2024
Kind
B2
Abstract

Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.

Claims (25)

1. A fusion protein comprising a Type II CRISPR-Cas protein nickase and a deaminase, wherein said deaminase comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 407 and has adenine deaminase activity, and wherein said nickase

(a) is a Cas9 nickase; or

(b) comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397, or 398.

2. The fusion protein of claim 1 , wherein the nickase has the amino acid sequence of SEQ ID NO: 42.

3. The fusion protein of claim 1 , wherein the fusion protein further comprises at least one nuclear localization signal (NLS).

4. A cell comprising the fusion protein of claim 1 , wherein the cell further comprises a guide RNA.

5. A system for modifying a target DNA molecule comprising a target DNA sequence, said system comprising:

a) the fusion protein of claim 1 ; and

b) one or more guide RNAs (gRNAs) capable of hybridizing to said target DNA molecule or one or more nucleotide sequences encoding the one or more gRNAs; and

wherein the one or more gRNAs are capable of forming a complex with the fusion protein in order to direct said fusion protein to bind to and modify said target DNA molecule.

6. The system of claim 5 , wherein the nickase has the amino acid sequence of SEQ ID NO: 42.

7. A polypeptide having adenine deaminase activity and comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 407.

8. The polypeptide of claim 7 , wherein said polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 407.

9. The polypeptide of claim 7 , wherein said polypeptide has the amino acid sequence of SEQ ID NO: 407.

10. The polypeptide of claim 7 , wherein said polypeptide further comprises at least one nuclear localization signal.

11. An adenine base editor comprising the polypeptide of claim 7 and a Type II CRISPR-Cas nickase, wherein said nickase

(a) is a Cas9 nickase; or

(b) comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397, or 398.

12. The adenine base editor of claim 11 , wherein the adenine base editor introduces an A>G mutation in a DNA molecule.

13. The fusion protein of claim 1 , wherein said deaminase comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 407 and has adenine deaminase activity.

14. The fusion protein of claim 1 , wherein said deaminase comprises the amino acid sequence of SEQ ID NO: 407.

15. The fusion protein of claim 2 , wherein said fusion protein comprises the amino acid sequence of SEQ ID NO: 496.

16. The fusion protein of claim 1 , wherein the fusion protein further comprises a protein tag or a cell penetrating domain.

17. The fusion protein of claim 1 , wherein the nickase has the amino acid sequence of SEQ ID NO: 52, 53, 55-59, 61, 397, or 398.

18. The system of claim 5 , wherein the nickase has the amino acid sequence of SEQ ID NO: 52, 53, 55-59, 61, 397, or 398.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: BOWEN, TYSON D.; CRAWLEY, ALEXANDRA BRINER; ELICH, TEDD D.
To: LIFEEDIT THERAPEUTICS, INC.
Reel/Frame 068428/0862 →
CHANGE OF NAME Recorded Aug 28, 2024
From: LIFEEDIT THERAPEUTICS, INC.
To: LIFE EDIT THERAPEUTICS, INC.
Reel/Frame 068807/0720 →
Continuity (5)
Continuation 17851880 · Jun 28, 2022
Continuation PCTUS2021049853 · Sep 10, 2021
Provisional Application 63146840 · Feb 8, 2021
Provisional Application 63077089 · Sep 11, 2020
Related Publication 20230002747A1 · Jan 5, 2023